Credit Suisse First Boston (CSFB), has been appointed sole bookrunner for the flotation of Ark Therapeutics, the healthcare group, in the bank's fourth initial public offering (IPO) win in Europe this year.

Nomura, which has a 14% stake in Ark, has been appointed co-lead manager with CSFB, the investment banking arm of Credit Suisse. The IPO will be completed next month. The indicative price range is 120p to 146p per share valuing the company at up to £135m (€200m).